CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 500 target
Drug / intervention
Intravenous and Intranasal BMSCprocedure
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Have documented functional damage to central or peripheral nervous system unlikely to improve with current standard of care
  • ✓At least 6 months post-onset of disease
  • ✓If on current medical therapy, must be stable and unlikely to have reversal of neurologic functional damage from ongoing treatment
  • ✓Potential for improvement with BMSC treatment with minimal risk of harm from procedure per Dr. Weiss and neurologists
Key exclusion· 2
  • ✕Women of childbearing age must not be pregnant at time of treatment and should refrain from pregnancy for 3 months post-treatment
  • ✕Patients not medically stable or at significant risk to health undergoing procedure are not eligible

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02795052
NCT02795052N/ARecruitingHigh Momentum
Long Recruiting
CompareCT.gov

Neurologic Bone Marrow Derived Stem Cell Treatment Study

MD Stem Cells·interventional·Posted Jun 9, 2016·Updated Jun 26, 2026

In Brief

A clinical study evaluating Intravenous and Intranasal BMSC for Neurologic Disorders and 25 related conditions. Currently recruiting, targeting 500 participants across 3 sites in 2 countries.

Signals

Enrolling ahead of pace

Detailed Summary

This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
CountriesUnited Arab Emirates, United States
Collaborators--

Timeline

N/ARecruiting
201720182019202020212022202320242025202620272028
First PostedJun 9, 2016
Enrollment StartJun 1, 2016
Primary CompletionJul 31, 2027
Study CompletionJul 31, 2028
TodayJul 2, 2026
Enrollment to primary: 11.2 yearsPosted 10.1 years agoPrimary completion in 1.1 years

Interventions

Intravenous and Intranasal BMSCprocedure

Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)